“You see, foreign companies also publish their profits and compare them to past performance. For example, Amgen reported higher third-quarter profits, driven by a 24% increase in sales of cholesterol and osteoporosis drugs.
The adjusted earnings per share for this American biotechnology company in the third quarter of 2024 rose by 13% from the same period last year, reaching $5.58 per share, surpassing analysts’ estimates of $5.11, according to data from the London Stock Exchange Group (LSEG).
However, Amgen’s third-quarter revenue of $8.5 billion was in line with analysts’ estimates of $8.52 billion.
Amgen is conducting a study on a weight loss drug called AMG513 and has plans for a final phase safety study on the experimental immunotherapy drug xaluritamig in men with advanced prostate cancer.”
